Spots Global Cancer Trial Database for Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Official Title: Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia
Study ID: NCT03283228
Conditions
Interventions
Study Description
Brief Summary: 1. Detect the expression of marker CD56 and CD11b in newly diagnosed cases of adult AML. 2. Study correlation between CD56 and CD11b expression with haematological parameters in cases of adult AML.
Detailed Description: 1. CD11b expression level is a prognostic biomarker for AML patient. CD11b positivity could predict a poor prognosis for AML patients. 2. CD56 antigen expression, an inexpensive, easy to detect and reproduce index, is closely related to the prognosis of AML patients
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
